中图分类号：
R969.4
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] MANTADAKIS E,COLE P D,KAMEN B A. High-dose methotrexate in acute lymphoblastic leukemia:Where is the evidence for its continued use [J]. Pharmocotherapy,2005,25(5):748-755.
[2] HUANG L, TISSING W J, DE J R, et al. Polymorphisms in folate-related genes:Association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia [J]. Leukemia, 2008,22 (9) :1798-1800.
[3] PANG L, LIU L M, ZHAO L M. Research progress in influence factors of excretion delay of high-dose methotrexate[J]. Chin Pharm J(中国药学杂志), 2013,48(22):1892-1896 .
[4] GANGJEE A, JAIN H, KURUP S. Recent advances in classical and non-classicalantifolates as antitumor and antiopportunistic infection agents[J]. Anti-cancer Agents Med Chem, 2007, 7(5):514-542.
[5] LECLERC G J, MOU C,LECLERC G M,et al.Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia:Implications for combination therapy[J]. Leukemia,2010,24(3):552-562.
[6] Pediatric Hematology Group of Chinese Medical Association,Editorial Board of Chinese Journal of Pediatrics. Diagnosis and treatment of childhood acute lymphoblastic leukemia (third recension protocol)[J]. Chin J Pediatr(中华儿科杂志),2006,44(5):392-395.
[7] SHARMA S,DAS M,KUMAR A, et al.Purine biosynthetic pathway genes andmethotrexate response in rheumatoid arthritis patients among north Indians[J]. Pharmacogenet Genom, 2009,19(10):823-828.
[8] ZENG D X,XIANG F.Determination of methotrexatelevel in plasma by reversed phase high performance liquid chromatography[J]. Herald Med(医药导报),2004, 23(3):194-195.
[9] SUN W,MA L,HAN Z W, et al.Pharmacokinetics of high-dose methotrexate in the treatment of pediatric lymphocytic leukemia [J]. Chin Pharm J(中国药学杂志),2002,37(10):768-770.
[10] IZBICKA E, DIAZ A, STREEPER R, et al. Distinct mechanistic activity prowle ofpralatrexate in comparison to other antifolates in in vitro and in vivo models ofhuman cancers [J].Cancer Chem Pharm, 2009, 64(5):993-999.
[11] ESTI L, LILAH R, MARLENE A, et al. Loss of folypoly-γ-glutamate synthetase activityis a dominant mechanism of resistance to polyglutamaylation-dependent novelantifolates in multiple human leukemia sublines[J].Inter J Cancer,2003,103(5):587-599.
[12] LECLERC G J,YORK T A,HSIEH K T,et al.Molecular basis for decreased folypoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutatant cell line[J].Leuk Res,2007,31(3):293-299.
[13] WANG S M, SUN L L, ZENG W X, et al. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia[J].Cancer Chem Pharm, 2014,74(2):283-289.
[14] SHARMA S, DAS M, KUMAR A, et al. Interaction of genes frominflux-metabolism-efflux pathway and their influence on methotrexate efficacy inrheumatoid arthritis patients among Indians[J].Pharmacogenet Genom,2008, 18(12):1041-1049.
[15] LIU S G,LI Z G,CUI L,et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population[J].Leuk Lymphoma,2011,52(6):1030-1040.
[16] PANETTA J C, SPARREBOOM A, PUI C H,et al. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells[J]. PLoS Comput Biol, 2010, 6(12):e1001019.
[17] XU H,ZHANG Y N,KANG X X. The relationship between methylene tetrahydrofolate reductase gene polymorphism and serum concentration of methotrexate in children with acute lymphoblastic leukemia[J]. Chin J Lab Diagn(中国实验诊断学),2010 ,14(5):676-679.
[18] ZHANG H H,YUE L J,CHEN X W. Polymorphism of gamma-glutamy hydrolase and methotrexate sensitiveity[J]. Inter J Pediat(国际儿科学杂志),2011,38(5):497-500.
[19] LI H,JIANG H. Association between the drug-metabolizing enzyme gene polymorphism and toxicity of methotrexate in childhood acute lymphoblastic leukemia[J]. Inter J Pediat(国际儿科学杂志),2012 ,39(3):274-276.
[20] SUN L,SHEN Z J. Folylpoly-gamma-glutamate synthetase and anti-tumor drug resistant[J]. Chem Life(生命的化学),2010 ,30(2):299-302.
[21] STARK M,WICHMAN C,AVIVI I, et al.Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia[J]. Blood,2009,113(18):4362-4369.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
温州市科技计划资助项目(Y20140255)
{{custom_fund}}
PDF(976 KB)
